Develops biologic drugs and novel oncology therapeutics using its proprietary biotechnology platforms.
Xenetic Biosciences, Inc. is a pioneering biopharmaceutical company dedicated to advancing innovative therapies in oncology. Central to our mission is the development of XCART, a groundbreaking personalized chimeric antigen receptor T cell (CAR T) platform technology. This platform is engineered to precisely target patient-specific tumor neoantigens, enhancing the effectiveness of cancer treatments. Our research and development efforts focus on biologic drugs and oncology therapeutics, particularly cell-based therapies tailored to target B-cell lymphomas by addressing the B-cell receptor on malignant tumor cells.
In addition to our pioneering work in oncology, Xenetic Biosciences harnesses PolyXen, a proprietary drug delivery platform. This platform facilitates partnerships with leading biotechnology and pharmaceutical companies to develop enhanced therapeutic solutions. Collaborations with esteemed partners like Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC underscore our commitment to leveraging innovative science to address unmet medical needs.
Headquartered in Framingham, Massachusetts, Xenetic Biosciences is strategically positioned at the forefront of biopharmaceutical innovation. Through our cutting-edge technologies and strategic partnerships, we aim to revolutionize cancer treatment paradigms and improve outcomes for patients worldwide.